Our top pick for
StarTek Inc is a specialty business services business based in the US. StarTek shares (SRT) are listed on the NYSE and all prices are listed in US Dollars. StarTek employs 42,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.77|
|52-week range||$4.95 - $9.80|
|50-day moving average||$5.56|
|200-day moving average||$6.68|
|Wall St. target price||$11.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||1.94%|
|1 month (2021-09-24)||7.85%|
|3 months (2021-07-23)||-21.28%|
|6 months (2021-04-23)||-30.15%|
|1 year (2020-10-23)||10.96%|
|2 years (2019-10-24)||-11.09%|
|3 years (2018-10-24)||2.67%|
|5 years (2016-10-24)||6.69|
Valuing StarTek stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of StarTek's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
StarTek's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.04. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into StarTek's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
StarTek's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $73.6 million.
The EBITDA is a measure of a StarTek's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$689.3 million|
|Operating margin TTM||6.72%|
|Gross profit TTM||$89.6 million|
|Return on assets TTM||4.63%|
|Return on equity TTM||-1.73%|
|Market capitalisation||$230.9 million|
TTM: trailing 12 months
There are currently 173,697 StarTek shares held short by investors – that's known as StarTek's "short interest". This figure is 1.9% down from 177,119 last month.
There are a few different ways that this level of interest in shorting StarTek shares can be evaluated.
StarTek's "short interest ratio" (SIR) is the quantity of StarTek shares currently shorted divided by the average quantity of StarTek shares traded daily (recently around 34739.4). StarTek's SIR currently stands at 5. In other words for every 100,000 StarTek shares traded daily on the market, roughly 5000 shares are currently held short.
However StarTek's short interest can also be evaluated against the total number of StarTek shares, or, against the total number of tradable StarTek shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case StarTek's short interest could be expressed as 0% of the outstanding shares (for every 100,000 StarTek shares in existence, roughly 0 shares are currently held short) or 0.0144% of the tradable shares (for every 100,000 tradable StarTek shares, roughly 14 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against StarTek.
Find out more about how you can short StarTek stock.
We're not expecting StarTek to pay a dividend over the next 12 months.
Over the last 12 months, StarTek's shares have ranged in value from as little as $4.95 up to $9.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while StarTek's is 1.3141. This would suggest that StarTek's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
StarTek, Inc. , a business process outsourcing company, provides omni-channel customer experience, digital transformation, and technology services in various markets. The company primarily offers customer engagement, omnichannel engagement, social media, customer intelligence analytics, work from home, back office, and receivables management services under the Startek and Aegis brands. It also offers Startek cloud, a hybrid omni-cloud platform integrated with AI capabilities. The company serves telecommunications, e-commerce and consumer, media and cable, financial and business services, travel and hospitality, healthcare and education, technology, and energy and utility industries in the Americas, the Middle East, Malaysia, India, Sri Lanka, Argentina, Peru, and internationally. StarTek, Inc. was founded in 1987 and is based in Greenwood Village, Colorado.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.